Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have earned a consensus recommendation of “Buy” from the eight research firms that are covering the company, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $81.29.

A number of brokerages have recently commented on GPCR. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. William Blair began coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an “outperform” rating on the stock. Finally, Stifel Nicolaus started coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its stake in shares of Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after purchasing an additional 221,851 shares during the period. FMR LLC boosted its stake in Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after buying an additional 383,635 shares in the last quarter. Janus Henderson Group PLC grew its position in Structure Therapeutics by 5.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company’s stock valued at $112,816,000 after acquiring an additional 203,010 shares during the period. Deep Track Capital LP raised its stake in Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after acquiring an additional 1,579,492 shares in the last quarter. Finally, Vestal Point Capital LP lifted its holdings in shares of Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $46,782,000 after acquiring an additional 575,000 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Price Performance

Shares of GPCR opened at $17.31 on Tuesday. The company has a market capitalization of $992.61 million, a PE ratio of -23.39 and a beta of -2.37. Structure Therapeutics has a one year low of $17.24 and a one year high of $62.74. The company’s fifty day moving average price is $23.99 and its 200 day moving average price is $31.00.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Analysts anticipate that Structure Therapeutics will post -0.82 earnings per share for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.